Experimental data showed that isolated CD28+ T cells obtained from end-stage renal disease patients exposed to allostimulation in the presence of belatacept differentiated into CD28− T cells producing high amounts of IFN-γ and were able to mediate allogeneic response [45]. This evidence concerns the gene CD28 and stage 5 chronic kidney disease.